|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.36 USD | +0.05% |
|
+0.24% | +34.38% |
| 05-22 | CVC, GBL launch EUR10.7 billion bid for Italian drugmaker Recordati | RE |
| 05-11 | Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise | MT |
Company Valuation: Catalyst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 698.1 | 1,936 | 1,792 | 2,489 | 2,869 | 3,835 | - | - |
| Change | - | 177.28% | -7.42% | 38.9% | 15.25% | 33.7% | - | - |
| Enterprise Value (EV) | 506.8 | 1,637 | 1,655 | 1,972 | 2,160 | 3,835 | 3,835 | 3,835 |
| Change | - | 223.05% | 1.05% | 19.17% | 9.53% | 77.6% | 0% | 0% |
| P/E Ratio | 18.3x | 24.8x | 26.7x | 15.9x | 13.9x | 16.5x | 13.6x | 12.1x |
| PBR | 3.53x | 6.9x | 4.93x | 3.47x | 3x | - | - | - |
| PEG | - | 0x | -1.7x | 0x | 0.5x | 1.3x | 0.7x | 1x |
| Capitalization / Revenue | 4.96x | 9.04x | 4.5x | 5.06x | 4.87x | 6.07x | 5.38x | 4.85x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 6.07x | 5.38x | 4.85x |
| EV / EBITDA | - | - | - | 0x | 0x | 11.9x | 9.74x | 9.56x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 13.5x | 10.9x | 9.64x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 17.4x | 14.2x | 12.2x |
| FCF Yield | 8.5% | 5.99% | 8% | 9.61% | 7.27% | 5.76% | 7.07% | 8.19% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 | 1.9 | 2.298 | 2.58 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 140.8 | 214.2 | 398.2 | 491.7 | 589 | 632 | 713.1 | 790.8 |
| EBITDA 1 | - | - | - | 255.1 | 320.4 | 321.4 | 393.9 | 401.4 |
| EBIT 1 | 52.38 | 101.8 | 86.81 | 195.1 | 257.8 | 284.9 | 351.1 | 398.1 |
| Net income 1 | 39.48 | 83.08 | 71.41 | 163.9 | 214.3 | 238.1 | 291 | 320 |
| Net Debt | -191.3 | -298.4 | -137.6 | -517.6 | -709.2 | - | - | - |
| Reference price 2 | 6.77 | 18.60 | 16.81 | 20.87 | 23.34 | 31.34 | 31.34 | 31.34 |
| Nbr of stocks (in thousands) | 103,118 | 104,071 | 106,611 | 119,273 | 122,912 | 122,381 | - | - |
| Announcement Date | 3/16/22 | 3/15/23 | 2/28/24 | 2/26/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.49x | - | - | -.--% | 3.84B | |
| 15.58x | 3.36x | 9.06x | 0.65% | 61.21B | |
| 28.52x | 5.78x | 16.7x | 0.55% | 58.15B | |
| 32.09x | 10.84x | 20.46x | -.--% | 39.54B | |
| -46.6x | 2.86x | 8.43x | 3.94% | 35.08B | |
| 31.36x | 3.42x | 10.31x | -.--% | 28.68B | |
| 17.06x | 2.86x | 8.84x | -.--% | 21.06B | |
| -5.32x | 7.01x | -4.29x | -.--% | 18.25B | |
| 47.8x | 5.06x | 36.34x | -.--% | 16.49B | |
| 24.35x | 5.04x | 13.6x | -.--% | 15.87B | |
| Average | 16.13x | 5.14x | 13.27x | 0.52% | 29.82B | |
| Weighted average by Cap. | 15.58x | 5.16x | 13.08x | 0.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CPRX Stock
- Valuation Catalyst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
